Atopic Dermatitis (AD) Treatment Market by Drug Class (Brand) – Interleukin Inhibitors – Dupilumab (Dupixent); Phosphodiesterase-4 (PDE4) Inhibitors – Crisaborole (Eucrisa); Systemic Therapy (Phototherapy); Topical Corticosteroids; Topical Immunomodulators / Topical Calcineurin Inhibitors (TCI) – Pimecrolimus (Elidel), Tacrolimus (Protopic) and Forecast 2017-2021

Atopic Dermatitis (AD) Treatment Market by Drug Class (Brand) – Interleukin Inhibitors – Dupilumab (Dupixent); Phosphodiesterase-4 (PDE4) Inhibitors – Crisaborole (Eucrisa); Systemic Therapy (Phototherapy); Topical Corticosteroids; Topical Immunomodulators / Topical Calcineurin Inhibitors (TCI) – Pimecrolimus (Elidel), Tacrolimus (Protopic) and Forecast 2017-2021

Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. It is a multifaceted, chronic relapsing inflammatory skin disease that is commonly associated with other atopic manifestations such as food allergy, allergic rhinitis, and asthma. It affects people of all ages but more common among infants and children. Risk factors for atopic dermatitis are mainly categorized as modifiable and non-modifiable. Modifiable risk factors include inhalant and food allergens however; non-modifiable risk factors include genetics or heritability.

AD therapy mainstay includes use of emollients, topical/oral corticosteroids, calcineurin inhibitors, and for severe AD – phototherapy and systemic immunomodulators. Standard treatments for AD attempt to reduce inflammation and pruritus with combinations of emollients, topical corticosteroids, and topical immunomodulators. Additionally, systemic immunomodulators, and in some cases UV phototherapy, are used to treat AD. Treatment with topical therapies and anti-inflammatory agents is often successful; however, more-effective therapies for treatment-refractory AD represent an area of tremendous unmet need.

When topical treatments fail, systemic therapies are required. Systemic anti-inflammatory therapy is appropriate for severe AD patients; about 10% of adult patients receive systemic anti-inflammatory therapy at some point during the course of their disease, while in children it is rarely employed. Artificial UV radiation is frequently used as a second-line treatment for moderate-to-severe AD in adults. Non-biologic systemic drugs used for adult AD include corticosteroids, cyclosporine, azathioprine, mycophenolate mofetil and methotrexate, which exert their immunosuppressive effects by reducing the disease inflammatory cell numbers and proinflammatory cytokines expression. All these agents are used off label, except for cyclosporine, which is licensed and approved for short-term treatment of severe refractory AD in many European countries. Long-term treatment with oral immunosuppressive therapy is usually introduced when topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors is not successful. Cyclosporine is the most widely used agent, administered with excellent effects as short-term treatment as well as maintenance therapy in both adults and children. In addition, other immunosuppressive agents such as azathioprine, mycophenolate mofetil and methotrexate may be helpful for the treatment of relapsing and severe forms of AD.

U.S. Food and Drug Administration approved Sanofi’s and Regeneron’s Dupixent (dupilumab) in March 2017. Pfizer’s Eucrisa (Crisaborole) was approved by the FDA in December 2016. Eucrisa (Crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). In clinical trials, Eucrisa was shown to reduce symptoms of AD such as itching, redness, lichenification (thickened skin), weepy rash, and raw, scratched lesions. Strong Pipeline molecules in the clinical phases II and III include Tralokinumab, ANB-020, Baricitinib, BMS-981164, Lebrikizumab, Mepolizumab, MM36, Nemolizumab, PF-04965842, Tezepelumab, Upadacitinib, ZPL-389, and MEDI-9314.

The global atopic dermatitis treatment market segmentation is based on drug class (brand) – interleukin inhibitors – dupilumab (Dupixent); phosphodiesterase-4 (PDE4) inhibitors – crisaborole (Eucrisa); systemic therapy (phototherapy); topical corticosteroids; topical immunomodulators / topical calcineurin inhibitors (TCI) – pimecrolimus (Elidel), and tacrolimus (Protopic).

The global atopic dermatitis treatment market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global atopic dermatitis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global atopic dermatitis treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global atopic dermatitis treatment market and profiled in this report include AbbVie Inc., AnaptysBio, AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly & Company, Galderma, GlaxoSmithKline, LEO Pharma A/S, Medimetriks, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Valeant Pharmaceuticals, and Ziarco.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Atopic Dermatitis (AD) Treatment Market

1. Drug Class (Brand)
1.1. Interleukin Inhibitors
1.1.1. Dupilumab (Dupixent)
1.2. Phosphodiesterase-4 (PDE4) Inhibitors
1.2.1. Crisaborole (Eucrisa)
1.3. Systemic Therapy (Phototherapy)
1.4. Topical Corticosteroids
1.5. Topical Immunomodulators/ Topical Calcineurin Inhibitors (TCI)
1.5.1. Pimecrolimus (Elidel)
1.5.2. Tacrolimus (Protopic)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie Inc.
3.2. AnaptysBio
3.3. AstraZeneca
3.4. Bristol-Myers Squibb
3.5. Chugai
3.6. Eli Lilly & Company
3.7. Galderma
3.8. GlaxoSmithKline
3.9. LEO Pharma A/S
3.10. Medimetriks
3.11. Novartis
3.12. Pfizer
3.13. Regeneron Pharmaceuticals Inc.
3.14. F. Hoffmann-La Roche AG
3.15. Sanofi S.A.
3.16. Valeant Pharmaceuticals
3.17. Ziarco

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*